Connect with us

Business

CV Sciences Inc (OTCMKTS: CVSI) and University of California Inspire Hope for Nicotine Dependence Treatment after the Publication of a Cannabidiol Efficacy Study

Published

on

CV Sciences Inc (OTCMKTS: CVSI) has been performing remarkably as a company focusing on hemp-derived cannabidiol (CBD) products, and today it highlights its plans for the future. First, it seeks to develop and commercialize its CBD-based pharmaceutical, an undertaking it hopes will enable it to treat persons struggling with nicotine addiction.

The collaboration and its essence

It partners with researchers from the University of California to publish a preclinical study that has adequately demonstrated the effectiveness and efficacy of chronic CBD treatment in eliminating nicotine dependence among the affected persons. The focus on dealing with the withdrawal symptoms has been one of the most critical lines of thought in the whole undertaking. 

The study also turned to animal models, and the results are out. Through animal models, scientists have come to recognize the effects of CBD in minimizing the craving for alcohol and cocaine. In addition, they discovered the effects of the substance in the modulation of the nicotinic receptor function as well. 

Researchers opened up on their findings of the study involving rats, in which case these rodents were treated with CBD. The rats in question had been dependent on nicotine, and there was the need to focus on the withdrawal symptoms. 

Scientists administered the treatment that prevented the animal from showing withdrawal symptoms such as weight gain and increased pain sensitivity during the short- and long-term nicotine restriction phase. 

Dowling’s perspective

The Chief Executive Officer of CV Sciences, Joseph Dowling, seems pretty excited about the outcome of the research conducted together with UC San Diego.

Dowling opined, “This study marked a key milestone in CV Sciences’ smokeless tobacco addiction treatment R&D efforts and further extends our potential product development opportunities to commercialize the world’s first and only FDA-approved treatment for smokeless tobacco addiction to address a huge unmet medical need and global health issue.”

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.

FEATURED STORIES